Robotic gloveless isolator technology enhances regional production of advanced therapeutics

The increasing complexity of advanced therapy manufacturing, driven by smaller batch sizes, higher drug substance cost, and stricter regulatory guidelines, necessitates a shift toward more agile and precise production systems. Robotic gloveless isolator (RGI) technology addresses critical challenges in aseptic fill-finish operations by minimizing contamination risk and product loss, particularly for sensitive modalities such as plasmid DNA, viral vectors, mRNA, and recombinant proteins.